JHL Biosimilar Pipeline
Potential Indication / Disease Area
Osteoporosis, Bone CancerBone Loss, Bone pain, Fracture Bone, Spinal Cord Compression, Bone destruction, Giant cell tumor of the bone, High risk of fracture, Refractory Hypercalcemia of malignancy
A fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL)
Clinical Phase I 2020
JHL1266 is a proposed biosimilar to denosumab, which is a monoclonal antibody used for treatment of a range of osteoporosis.
A cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
Psoriasis, Crohn’s Disease
Human monoclonal antibody that is directed against interleukin 12 and interleukin 23
Pre-Clinical Stage (Selecting Clone in progress)
JHL1255 is a proposed biosimilar to ustekinumab, a human monoclonal antibody that is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Human IgG1 that binds to VEGFR2
JHL1178 is a proposed biosimilar to ramucirumab, a human IgG1 that binds to VEGFR2, which in turn blocks the natural ligands secreted by tumors, therefore can inhibit tumor angiogenesis.